Literature DB >> 19749993

Aliskiren (tekturna), a novel antihypertensive approach to inhibition of the Renin-Angiotensin-aldosterone system.

Julie Cromer, Simona Peker.   

Abstract

Year:  2008        PMID： 19749993      PMCID： PMC2730067     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  15 in total

1.  Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.

Authors:  Alan H Gradman; Roland E Schmieder; Robert L Lins; Juerg Nussberger; Yanntong Chiang; Martin P Bedigian
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

2.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Authors:  James L Pool; Roland E Schmieder; Michel Azizi; Jean-Claude Aldigier; Andrzej Januszewicz; Walter Zidek; Yanntong Chiang; Andrew Satlin
Journal:  Am J Hypertens       Date:  2007-01       Impact factor: 2.689

3.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Wayne Rosamond; Katherine Flegal; Gary Friday; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Michael Ho; Virginia Howard; Brett Kissela; Bret Kissela; Steven Kittner; Donald Lloyd-Jones; Mary McDermott; James Meigs; Claudia Moy; Graham Nichol; Christopher J O'Donnell; Veronique Roger; John Rumsfeld; Paul Sorlie; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Yuling Hong
Journal:  Circulation       Date:  2006-12-28       Impact factor: 29.690

4.  Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

Authors:  Alberto Villamil; Steven G Chrysant; David Calhoun; Bonnie Schober; Huang Hsu; Linda Matrisciano-Dimichino; Jack Zhang
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

Review 5.  Renin inhibition with aliskiren: where are we now, and where are we going?

Authors:  Michel Azizi; Randy Webb; Juerg Nussberger; Norman K Hollenberg
Journal:  J Hypertens       Date:  2006-02       Impact factor: 4.844

6.  Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

Authors:  Eoin O'Brien; John Barton; Juerg Nussberger; David Mulcahy; Chris Jensen; Patrick Dicker; Alice Stanton
Journal:  Hypertension       Date:  2006-12-11       Impact factor: 10.190

7.  Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.

Authors:  Alice Stanton; Chris Jensen; Juerg Nussberger; Eoin O'Brien
Journal:  Hypertension       Date:  2003-11-03       Impact factor: 10.190

8.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

Review 10.  Renin-angiotensin system and cardiovascular risk.

Authors:  Roland E Schmieder; Karl F Hilgers; Markus P Schlaich; Bernhard M W Schmidt
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321
View more
  1 in total

1.  Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.

Authors:  Ayad K Ali
Journal:  Ther Clin Risk Manag       Date:  2011-08-09       Impact factor: 2.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.